Lawrence Sher
Overview
Explore the profile of Lawrence Sher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
2165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Soens M, Ananworanich J, Hicks B, Lucas K, Cardona J, Sher L, et al.
Vaccine
. 2025 Feb;
50:126847.
PMID: 39919447
Background: Messenger RNA (mRNA)-based influenza vaccines have the potential to improve upon limitations of current vaccine approaches to seasonal influenza. Methods: Here we report findings on the primary and secondary...
2.
Jackson D, Bacharier L, Phipatanakul W, Sher L, Domingo C, Papadopoulos N, et al.
Ann Allergy Asthma Immunol
. 2023 Mar;
131(1):44-51.e4.
PMID: 36958470
Background: Type 2 inflammation is common in children with asthma. Dupilumab, a human antibody, blocks the signaling of interleukin -4 and -13, key and central drivers of type 2 inflammation....
3.
Fowler J, Sugarman J, Sher L, Zang C, Werth J, Myers D, et al.
Dermatol Ther (Heidelb)
. 2023 Feb;
13(4):951-960.
PMID: 36811773
Introduction: Using data from three clinical trials, the effect of crisaborole treatment on sleep outcomes for pediatric patients with atopic dermatitis (AD) and their families was examined. Methods: This analysis...
4.
Castro M, Kerwin E, Miller D, Pedinoff A, Sher L, Cardenas P, et al.
EClinicalMedicine
. 2021 May;
35:100847.
PMID: 33997741
Background: These studies assessed the efficacy and safety of fevipiprant, an oral antagonist of the prostaglandin D (PGD) receptor (DP), compared with placebo when added to standard-of-care (SoC) asthma therapy...
5.
Bansal A, Simpson E, Paller A, Siegfried E, Blauvelt A, de Bruin-Weller M, et al.
Am J Clin Dermatol
. 2021 Jan;
22(1):101-115.
PMID: 33481203
Background: Conjunctivitis is a known comorbidity of atopic dermatitis. Dupilumab clinical trials for moderate-to-severe atopic dermatitis in adults showed a higher conjunctivitis incidence for dupilumab-treated patients than placebo-treated patients, whereas...
6.
Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis
Boguniewicz M, Beck L, Sher L, Guttman-Yassky E, Thaci D, Blauvelt A, et al.
J Allergy Clin Immunol Pract
. 2021 Jan;
9(3):1212-1223.e6.
PMID: 33453450
Background: Dupilumab has demonstrated efficacy with acceptable safety in clinical trials in patients with moderate to severe atopic dermatitis (AD). Objective: To assess dupilumab's impact on asthma and sinonasal conditions...
7.
Vickery B, Vereda A, Nilsson C, Du Toit G, Shreffler W, Burks A, et al.
J Allergy Clin Immunol Pract
. 2020 Dec;
9(5):1879-1889.e13.
PMID: 33359589
Background: The randomized, controlled PALISADE trial demonstrated the benefit of daily oral immunotherapy with Peanut (Arachis Hypogaea) allergen powder-dnfp (PTAH, formerly AR101) in peanut-allergic children and adolescents. Objective: ARC004, the...
8.
Paller A, Siegfried E, Thaci D, Wollenberg A, Cork M, Arkwright P, et al.
J Am Acad Dermatol
. 2020 Jun;
83(5):1282-1293.
PMID: 32574587
Background: Children with severe atopic dermatitis (AD) have limited treatment options. Objective: We report the efficacy and safety of dupilumab + topical corticosteroids (TCS) in children aged 6-11 years with...
9.
Beck L, Thaci D, Deleuran M, Blauvelt A, Bissonnette R, de Bruin-Weller M, et al.
Am J Clin Dermatol
. 2020 Jun;
21(4):567-577.
PMID: 32557382
Background: Management of moderate-to-severe atopic dermatitis (AD) commonly requires long-term treatment. Objective: The aim of this study was to report the safety and efficacy of dupilumab treatment for up to...
10.
Simpson E, Paller A, Siegfried E, Boguniewicz M, Sher L, Gooderham M, et al.
JAMA Dermatol
. 2019 Nov;
156(1):44-56.
PMID: 31693077
Importance: Adolescents with atopic dermatitis (AD) have high disease burden negatively affecting quality of life, with limited treatment options. The efficacy and safety of dupilumab, a monoclonal antibody, approved for...